John B. Henneman III, Director at Anika Therapeutics, Inc. (ANIK), bought 5,000 shares at $14.66 ($73K) on 2026-05-01, disclosed to the SEC on 2026-05-04.
Open-market purchase of $73k ANIK by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| Filing → |
| RCM | SELL | 2023-08-09 | $1.7M | — | Filing → |
| ANIK | BUY | 2021-05-20 | $86K | — | Filing → |
| SPNE | SELL | 2020-08-05 | $150K | — | Filing → |